Does methotrexate cause fatty liver? Methotrexate is a widely used disease-modifying antirheumatic drug (DMARD) prescribed across the UK for rheumatoid arthritis, psoriasis, and psoriatic arthritis. Whilst highly effective at controlling inflammation, methotrexate carries a recognised risk of liver-related complications, including hepatic steatosis (fatty liver). However, there is no straightforward causal link—many patients taking methotrexate never develop fatty liver. When it does occur, it typically involves multiple factors including pre-existing metabolic conditions, obesity, diabetes, and alcohol consumption. With appropriate monitoring, folic acid supplementation, and lifestyle measures, the risk of significant liver complications can be substantially minimised, enabling safe long-term treatment.
Summary: Methotrexate may contribute to fatty liver (hepatic steatosis), but there is no direct causal link in all patients, and risk is influenced by multiple factors including obesity, diabetes, alcohol use, and pre-existing liver conditions.
- Methotrexate is a DMARD used for rheumatoid arthritis, psoriasis, and psoriatic arthritis with recognised hepatotoxicity risk.
- Fatty liver associated with methotrexate typically involves metabolic risk factors rather than the drug alone.
- Regular liver function monitoring (every 2 weeks initially, then monthly, then 12-weekly when stable) is essential for early detection.
- Folic acid supplementation (typically 5mg weekly) and limiting alcohol to ≤14 units per week reduce liver risk.
- Methotrexate is contraindicated in patients with significant hepatic impairment, chronic liver disease, or alcohol misuse.
- Seek urgent medical advice for jaundice, severe abdominal pain, confusion, or vomiting blood whilst taking methotrexate.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Does Methotrexate Cause Fatty Liver?
Methotrexate is a disease-modifying antirheumatic drug (DMARD) widely prescribed in the UK for conditions including rheumatoid arthritis, psoriasis, and psoriatic arthritis. Whilst methotrexate is highly effective at controlling inflammation and slowing disease progression, it does carry a recognised risk of hepatotoxicity—liver damage that can manifest in several forms.
Fatty liver disease (hepatic steatosis) is one potential liver-related complication associated with methotrexate use. The drug may contribute to hepatic steatosis through folate-dependent metabolic pathways and other mechanisms, though the precise relationship is not fully understood. It is important to recognise that there is no straightforward, direct causal link between methotrexate and fatty liver in all patients. Many individuals taking methotrexate do not develop fatty liver, and when it does occur, it is usually influenced by multiple factors including pre-existing liver conditions, alcohol consumption, obesity, type 2 diabetes, and metabolic syndrome.
Clinical evidence suggests that methotrexate-induced liver injury more commonly presents as elevated liver enzymes (transaminases) or, in rarer cases, fibrosis or cirrhosis with long-term use. Fatty infiltration of the liver may occur as part of a spectrum of hepatic changes. The MHRA and NICE emphasise the importance of regular monitoring to detect early signs of liver dysfunction, allowing timely intervention before serious damage occurs.
Methotrexate is contraindicated in patients with significant hepatic impairment, chronic liver disease, or alcohol misuse. Careful assessment is required before starting treatment, particularly in those with metabolic risk factors for fatty liver.
Patients should be reassured that with appropriate monitoring and adherence to safety guidelines—including folic acid supplementation and keeping alcohol intake well within UK low-risk limits (≤14 units per week, ideally less)—the risk of significant liver complications, including fatty liver, can be substantially minimised. Understanding these risks enables informed decision-making and safer long-term management of chronic inflammatory conditions.
References:
-
MHRA/EMC Summary of Product Characteristics for methotrexate
-
NHS: Methotrexate—side effects and monitoring
-
British Society for Rheumatology (BSR) DMARD monitoring guidance
Recognising Liver Problems While Taking Methotrexate
Early detection of liver problems is crucial for anyone taking methotrexate. Many liver-related issues develop gradually and may not cause noticeable symptoms in the initial stages. However, certain signs and symptoms should prompt immediate medical review.
Common symptoms of liver dysfunction include:
-
Persistent fatigue or unusual tiredness not explained by disease activity
-
Nausea, loss of appetite, or unexplained weight loss
-
Abdominal discomfort or pain, particularly in the upper right quadrant
-
Jaundice—yellowing of the skin or whites of the eyes
-
Dark urine or pale-coloured stools
-
Itching (pruritus) without an obvious skin cause
-
Easy bruising or bleeding
Emergency warning signs requiring immediate assessment (attend A&E or call 999) include:
-
Severe jaundice
-
Confusion, drowsiness, or altered mental state
-
Vomiting blood or passing black, tarry stools
-
Severe, unrelenting abdominal pain
It is important to note that many patients on methotrexate will experience mild, transient elevations in liver enzymes detected through routine blood monitoring. These often resolve spontaneously or with temporary dose adjustment and do not necessarily indicate serious liver damage. However, persistent or significantly elevated liver function tests require further investigation.
Fatty liver itself is often asymptomatic and typically identified through blood test abnormalities or imaging studies such as ultrasound. Non-alcoholic fatty liver disease (NAFLD) is increasingly common in the general population, particularly among individuals with metabolic syndrome, obesity, or type 2 diabetes. When fatty liver is detected in a patient taking methotrexate, careful clinical assessment is needed to determine whether it is related to the medication, underlying metabolic factors, or a combination of both.
Patients should maintain open communication with their healthcare team and report any new or worsening symptoms promptly. Do not stop or miss doses of methotrexate without medical advice. If you develop severe symptoms or signs of infection, you may be told to hold your next dose—contact your rheumatology team, GP, or NHS 111 urgently for guidance.
References:
-
NHS: Methotrexate—side effects and safety monitoring
-
NHS: Liver disease—symptoms and when to seek help
Monitoring and Reducing Liver Risks on Methotrexate
Regular monitoring is the cornerstone of safe methotrexate therapy. NICE, the British Society for Rheumatology (BSR), and the Specialist Pharmacy Service (SPS) recommend comprehensive baseline assessment before starting methotrexate, followed by ongoing surveillance throughout treatment.
Baseline investigations typically include:
-
Full blood count (FBC)
-
Liver function tests (LFTs): ALT, AST, alkaline phosphatase, bilirubin
-
Renal function tests (urea, creatinine, eGFR)
-
Baseline metabolic assessment: BMI, HbA1c (if diabetic or at risk), lipid profile
-
Hepatitis B and C screening for those at risk (this is routine in some specialties such as dermatology; follow local policies)
Ongoing monitoring typically follows BSR/SPS guidance: blood tests (FBC, LFTs, renal function) every 2 weeks for the first 6 weeks after starting or changing dose, then monthly for 3 months, then at least every 12 weeks once stable. The frequency may be adjusted based on individual risk factors, dose changes, or abnormal results. Always follow your local shared-care protocol.
Strategies to minimise liver risk include:
-
Folic acid supplementation: Typically 5mg once weekly (on a different day to methotrexate) reduces hepatotoxicity and other side effects
-
Alcohol limits: Keep well within UK Chief Medical Officers' low-risk drinking guidelines (≤14 units per week, spread over 3 or more days). Ideally drink less, or abstain entirely if you have additional liver risk factors. Patients with alcohol misuse should not take methotrexate.
-
Healthy body weight: Addressing obesity and metabolic syndrome reduces baseline fatty liver risk
-
Medication review: Avoid other hepatotoxic drugs where possible (e.g., concomitant leflunomide or retinoids require specialist oversight). Review over-the-counter medicines and herbal supplements with your pharmacist or GP.
-
Dose optimisation: Use the lowest effective dose
If liver enzymes become elevated, typical UK practice is to withhold or stop methotrexate and seek specialist advice if ALT or AST rises above twice the upper limit of normal (>2× ULN), or if lesser elevations persist. Follow your local shared-care protocol. Further investigation may include liver ultrasound, assessment for non-alcoholic fatty liver disease (NAFLD) using risk scores (e.g., FIB-4 or NAFLD Fibrosis Score per NICE NG49), transient elastography (FibroScan), or specialist hepatology referral to assess for fibrosis or cirrhosis.
Patients with pre-existing liver disease, significant alcohol history, obesity, diabetes, or metabolic syndrome require particularly careful assessment before starting methotrexate and closer monitoring during treatment.
References:
-
BSR guideline on DMARD safety monitoring (methotrexate)
-
Specialist Pharmacy Service (SPS): Methotrexate monitoring guidance
-
NICE NG49: Non-alcoholic fatty liver disease—assessment and management
-
UK Chief Medical Officers' low-risk drinking guidelines
When to Seek Medical Advice About Methotrexate and Your Liver
Knowing when to contact your healthcare team is essential for maintaining safety whilst taking methotrexate. Whilst routine monitoring appointments are scheduled regularly, certain situations require urgent or emergency medical attention.
Seek emergency help (attend A&E or call 999) if you experience:
-
Severe jaundice (yellowing of skin or eyes)
-
Confusion, drowsiness, or altered mental state
-
Vomiting blood or passing black, tarry stools
-
Severe, unrelenting abdominal pain
Contact your GP, rheumatology team, or NHS 111 urgently if you experience:
-
Jaundice (yellowing of skin or eyes)
-
Persistent abdominal pain
-
Unexplained bruising or bleeding
-
Dark urine combined with pale stools
-
Severe nausea or vomiting
-
Symptoms of infection alongside feeling generally unwell
Arrange a routine appointment (within a few days) if you notice:
-
Persistent fatigue significantly worse than usual
-
Loss of appetite lasting more than a few days
-
Mild abdominal discomfort
-
Generalised itching without obvious cause
-
Any new symptoms that concern you
If you have missed routine blood monitoring appointments, contact your surgery to rearrange these promptly. Regular blood tests are not optional—they are a critical safety measure. Some GP practices may withhold further methotrexate prescriptions if monitoring is overdue, which is appropriate clinical practice.
Patients should also inform their healthcare team about:
-
Starting any new medications (including over-the-counter medicines, herbal remedies, and supplements)
-
Changes in alcohol consumption
-
Significant weight gain or loss
-
New diagnoses of diabetes or other metabolic conditions
-
Planning pregnancy: Methotrexate must be stopped at least 3 months before attempting conception for both women and men. Confirm the exact timeframe with your specialist, as individual circumstances may vary.
Do not stop methotrexate without medical advice. If you develop severe symptoms or signs of infection, you may be told to hold your next dose pending clinical review—contact your rheumatology team, GP, or NHS 111 urgently for guidance. Abrupt discontinuation without advice can lead to serious disease flare. Your healthcare team can assess the situation, arrange appropriate investigations, and make informed decisions about whether to continue, adjust, or switch treatment.
Report suspected side effects: If you experience any side effect you think may be related to methotrexate, report it via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk or via the Yellow Card app.
With proper monitoring and patient-clinician partnership, methotrexate remains a safe and highly effective treatment for many chronic inflammatory conditions.
References:
-
MHRA/EMC SmPC: Methotrexate—pregnancy and contraception advice
-
NHS: Methotrexate—pregnancy, breastfeeding, and fertility
-
MHRA Yellow Card Scheme
Frequently Asked Questions
Can methotrexate damage your liver over time?
Yes, methotrexate can cause liver damage over time, though this is uncommon with proper monitoring. Liver injury may present as elevated liver enzymes, fatty liver, or in rare cases fibrosis or cirrhosis with long-term use. Regular blood tests (liver function tests) every 2 weeks initially, then monthly, then at least every 12 weeks when stable, allow early detection and timely intervention to prevent serious complications.
How does methotrexate affect fatty liver disease?
Methotrexate may contribute to hepatic steatosis (fatty liver) through folate-dependent metabolic pathways, though the exact mechanism is not fully understood. When fatty liver occurs in patients taking methotrexate, it is usually influenced by multiple factors including obesity, type 2 diabetes, metabolic syndrome, and alcohol consumption rather than the drug alone.
What are the warning signs of liver problems on methotrexate?
Warning signs include jaundice (yellowing of skin or eyes), persistent abdominal pain (especially upper right side), dark urine with pale stools, unexplained bruising or bleeding, severe nausea, and unusual fatigue. Seek emergency help immediately if you experience severe jaundice, confusion, vomiting blood, black tarry stools, or severe unrelenting abdominal pain whilst taking methotrexate.
Can I drink alcohol whilst taking methotrexate for arthritis?
You should keep alcohol well within UK low-risk drinking guidelines (≤14 units per week, spread over 3 or more days) whilst taking methotrexate, and ideally drink less or abstain entirely if you have additional liver risk factors. Methotrexate is contraindicated in patients with alcohol misuse, as combining the two significantly increases the risk of serious liver damage including fatty liver, fibrosis, and cirrhosis.
Is methotrexate safer than other DMARDs for liver health?
Methotrexate carries a recognised hepatotoxicity risk similar to other DMARDs such as leflunomide and sulfasalazine, though the specific liver effects differ between drugs. With appropriate monitoring (regular liver function tests), folic acid supplementation, and adherence to safety guidelines, methotrexate remains a safe and highly effective first-line DMARD for rheumatoid arthritis and other inflammatory conditions. Your rheumatology team will select the most appropriate DMARD based on your individual risk factors and medical history.
What happens if my liver blood tests are abnormal on methotrexate?
If liver enzymes (ALT or AST) rise above twice the upper limit of normal, typical UK practice is to withhold methotrexate and seek specialist advice immediately. Your healthcare team may arrange further investigations including liver ultrasound, risk scoring for fatty liver disease, or specialist hepatology referral to assess for fibrosis. Mild, transient elevations often resolve with temporary dose adjustment or brief treatment pause, and do not necessarily indicate serious liver damage.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
